<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Botulism immune globulin (intravenous human): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Botulism immune globulin (intravenous human): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Botulism immune globulin (intravenous human): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="13285" href="/d/html/13285.html" rel="external">see "Botulism immune globulin (intravenous human): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F142084"><span class="drugH1">Brand Names: US</span>
<ul>
<li>BabyBIG</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F142093"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Blood Product Derivative;</li>
<li>
                        Immune Globulin</li></ul></div>
<div class="block dop drugH1Div" id="F142090"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13285" href="/d/html/13285.html" rel="external">see "Botulism immune globulin (intravenous human): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b16dd9c-83f9-47c3-8546-b943fbe32c63">Infant botulism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infant botulism:</b> Dosage is specific to the manufactured lot; refer to product-specific labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: IV: 50 mg/kg as a single IV infusion; begin as soon as diagnosis of infant botulism is made.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51083168"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants: There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; the rate of infusion and concentration of solution should be minimized in patients with renal impairment or those at risk for renal dysfunction.</p></div>
<div class="block dohp drugH1Div" id="F51083169"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F142063"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined. Percentages reported in open-label study except where otherwise noted; may reflect pathophysiology of infant botulism.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure (transient, 75%), edema (18%), decreased blood pressure (transient, 16%), heart murmur (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Irritability (41%), decreased body temperature (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pallor (28%), contact dermatitis (24%), erythematous rash (22%, reported as 14% vs 8% in placebo-controlled study)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysphagia (65%), loose stools (25%), vomiting (20%), abdominal distension (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis media (11%, reported in placebo-controlled study)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Atelectasis (39%), rhonchi (34%), nasal congestion (18%), oxygen saturation decreased (17%), cough (13%), rales (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cold extremities (7%), tachycardia (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Agitation (10%), neurologic abnormality (neurogenic bladder)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (10%), hyponatremia (6%), metabolic acidosis (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Oral candidiasis (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (9%), anemia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (7%), erythema at injection site (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Abnormal breath sounds (decreased: 10%), stridor (9%), lower respiratory tract infection (8%), dyspnea (6%), tachypnea (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion related reaction (related to rate: &lt;5%, includes back pain, chills, fever, muscle cramps, nausea, vomiting, wheezing)</p></div>
<div class="block coi drugH1Div" id="F142075"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to human immune globulin preparations or any component of the formulation; selective immunoglobulin A deficiency</p></div>
<div class="block war drugH1Div" id="F142061"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur (some severe); patients with known antibodies to IgA are at greater risk; a severe fall in blood pressure may rarely occur with anaphylactic reaction; discontinue therapy and institute immediate treatment (including epinephrine 1 mg/mL) should be available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with immune globulin administration; may occur with rapid infusion and/or high doses of intravenous immune globulin (IGIV, ≥1 g/kg). Syndrome usually appears within several hours to 2 days following treatment; usually resolves within several days after product is discontinued. Female patients or patients with a migraine history may be at higher risk for AMS.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolysis: IGIV has been associated with antiglobulin hemolysis (acute or delayed). Cases of hemolysis-related renal impairment/failure or disseminated intravascular coagulation (DIC) have been reported. Risk factors associated with hemolysis include high doses (≥2 g/kg) given either as a single administration or divided over several days, underlying associated inflammatory conditions, and non-O blood type (FDA 2012). An underlying inflammatory state (eg, elevated C-reactive protein or erythrocyte sedimentation rate) may also increase the risk. Closely monitor patients for signs of hemolytic anemia, particularly in patients with preexisting anemia and/or cardiovascular or pulmonary compromise.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperproteinemia: Hyperproteinemia, increased serum viscosity, and hyponatremia may occur; distinguish hyponatremia from pseudohyponatremia to prevent volume depletion, a further increase in serum viscosity and a higher risk of thrombotic events.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Patients should be monitored for adverse events during and after the infusion. Stop administration with signs of infusion reaction (fever, chills, nausea, vomiting, and rarely shock). With other immune globulin products, risk may be increased with initial treatment, when switching brands of immune globulin, and with treatment interruptions of &gt;8 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with IGIV use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function. Usually occurs within 1 to 6 hours after infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Acute renal dysfunction (increased serum creatinine, oliguria, acute renal failure, osmotic nephrosis) can rarely occur and has been associated with fatalities in predisposed patients. Patients predisposed to renal dysfunction include patients with renal disease, diabetes mellitus, hypovolemia, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications due to risk of renal dysfunction. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. In patients at risk of renal dysfunction or acute renal failure, ensure adequate hydration prior to administration; the dose, rate of infusion, and concentration of solution should be minimized. Assess renal function prior to treatment and periodically thereafter. Discontinue if renal function deteriorates.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic events: Thrombosis may occur with immune globulin products even in the absence of risk factors for thrombosis. For patients at risk of thrombosis (eg, hypercoagulable conditions, history of venous or arterial thrombosis, indwelling central vascular catheters, hyperviscosity, cardiovascular risk factors, use of estrogens, prolonged immobilization, and advanced age), administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity, such as those with cryoglobulins, fasting chylomicronemia/severe hypertriglyceridemia, or monoclonal gammopathies.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution; ensure adequate hydration prior to administration; the rate of infusion and concentration of solution should be minimized.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adults: Not indicated for use in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents (eg, viruses, the variant Creutzfeldt Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt Jakob disease [CJD] agent) that could transmit disease, including unknown or emerging viruses and other pathogens. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: For IV infusion only; do not exceed recommended rate of administration.</p></div>
<div class="block foc drugH1Div" id="F142070"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">BabyBIG: 100 mg (1 ea) [contains albumin human]</p></div>
<div class="block geq drugH1Div" id="F142058"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58318426"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (BabyBIG Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $57,300.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F11217339"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Access to botulism immune globulin is restricted through the Infant Botulism Treatment and Prevention Program (IBTPP). Healthcare providers must contact the IBTPP on-call physician at (510) 231-7600 to review treatment indications and to obtain the medication.  For more information, refer to http://www.infantbotulism.org or contact <a class="__cf_email__" data-cfemail="4d040f191d1d0d24232b2c23392f22393821243e2063223f2a" href="/cdn-cgi/l/email-protection">[email protected]</a>.</p></div>
<div class="block admp drugH1Div" id="F52612318"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV infusion: Infusion should be started within 2 hours of reconstitution and be completed within 4 hours of reconstitution. <b>Do not administer IM or SubQ. </b></p>
<p style="text-indent:-2em;margin-left:2em;">Initial: Begin at 25 mg/kg/hour (0.5 mL/kg/hour) for the first 15 minutes; if well tolerated, may increase to a maximum rate of 50 mg/kg/hour (1 mL/kg/hour). Use low volume tubing for administration via a separate line. If this is not possible, piggyback BabyBIG into a preexisting line containing either NS or a dextrose solution (D2.5W, D5W, D10W, or D20W) with or without added NaCl. Do not dilute more than 1:2 with any of the above solutions. Drug concentration should be no less than 25 mg/mL. Administer via an in-line or syringe-tip filter (18 micron). Do not administer if solution is turbid. Epinephrine should be available for the treatment of acute allergic reaction.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Infusion reactions:</i> Slow the infusion rate or temporarily interrupt infusion for minor reaction (ie, flushing). Discontinue infusion and administer epinephrine for anaphylactic reaction or significant hypotension.</p></div>
<div class="block use drugH1Div" id="F142071"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">Treatment of infant botulism caused by toxin type A or B</p></div>
<div class="block mst drugH1Div" id="F6049723"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">BabyBIG may be confused with HBIG</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298879"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F142065"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for as long as 6 to 11 months following immune globulin administration. Recommendations vary by product and immune globulin dose, see full monograph for details.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F142076"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Botulism immune globulin is only indicated for use in infants &lt;1 year of age.</p></div>
<div class="block mop drugH1Div" id="F142067"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function (BUN, serum creatinine, urinary output); vital signs (continuously during infusion); signs and/or symptoms of allergic reaction (continuously during infusion); aseptic meningitis syndrome (may occur hours to days following IGIV therapy); signs of relapse (may occur up to 1 month following recovery)</p></div>
<div class="block pha drugH1Div" id="F142060"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">BIG-IV is purified immunoglobulin derived from the plasma of adults immunized with botulinum toxoid types A and B. BIG-IV provides antibodies to neutralize circulating toxins.</p></div>
<div class="block phk drugH1Div" id="F142074"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Half-life elimination: Infants: 28 days</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58187389"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Botulism antitoxin chiron behring</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16452558">
<a name="16452558"></a>Arnon SS, Schechter R, Maslanka SE, et al, "Human Botulism Immune Globulin for the Treatment of Infant Botulism," <i>N Engl J Med</i>, 2006, 354(5):462-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/botulism-immune-globulin-intravenous-human-drug-information/abstract-text/16452558/pubmed" id="16452558" target="_blank">16452558</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  BabyBIG (BIG-IV) (botulism immune globulin) [prescribing information]. Westlake Village, CA: Baxalta Inc; June 2021.</div>
</li>
<li>
<div class="reference">
                  FDA Safety Communication: updated information on the risks of thrombosis and hemolysis potentially related to administration of intravenous, subcutaneous and intramuscular human immune globulin products. November, 13, 2012. <a href="http://wayback.archive-it.org/7993/20170112095655/http:/www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm" target="_blank">http://wayback.archive-it.org/7993/20170112095655/http:/www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm</a>.</div>
</li>
<li>
<div class="reference">
                  Infant Botulism Treatment and Prevention Program, Department of Communicable Disease Control, California Department of Health Services, http://infantbotulism.org</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18055655">
<a name="18055655"></a>Underwood K, Rubin S, Deakers T, et al, "Infant Botulism: A 30-Year Experience Spanning the Introduction of Botulism Immune Globulin Intravenous in the Intensive Care Unit at Childrens Hospital Los Angeles," <i>Pediatrics</i>, 2007, 120(6):e1380-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/botulism-immune-globulin-intravenous-human-drug-information/abstract-text/18055655/pubmed" id="18055655" target="_blank">18055655</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8708 Version 125.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
